AR118510A1 - Métodos para la producción de células car-nk y sus usos - Google Patents
Métodos para la producción de células car-nk y sus usosInfo
- Publication number
- AR118510A1 AR118510A1 ARP200100857A ARP200100857A AR118510A1 AR 118510 A1 AR118510 A1 AR 118510A1 AR P200100857 A ARP200100857 A AR P200100857A AR P200100857 A ARP200100857 A AR P200100857A AR 118510 A1 AR118510 A1 AR 118510A1
- Authority
- AR
- Argentina
- Prior art keywords
- methods
- cells
- car
- production
- expanding
- Prior art date
Links
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 abstract 2
- 210000000822 natural killer cell Anatomy 0.000 abstract 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4613—Natural-killer cells [NK or NK-T]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
- A61K39/464412—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/804—Blood cells [leukemia, lymphoma]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2302—Interleukin-2 (IL-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
- C12N2502/1121—Dendritic cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Se proveen métodos para expandir células NK que expresan receptores de antígenos quiméricos y/o receptores de células T. También se proveen métodos para tratar enfermedades mediante la administración de las células CAR NK.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962826856P | 2019-03-29 | 2019-03-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR118510A1 true AR118510A1 (es) | 2021-10-20 |
Family
ID=72667448
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP200100857A AR118510A1 (es) | 2019-03-29 | 2020-03-27 | Métodos para la producción de células car-nk y sus usos |
Country Status (13)
Country | Link |
---|---|
US (1) | US20220325245A1 (es) |
EP (1) | EP3947647A4 (es) |
JP (1) | JP2022519935A (es) |
KR (1) | KR20220004992A (es) |
CN (1) | CN113811604A (es) |
AR (1) | AR118510A1 (es) |
AU (1) | AU2020254420A1 (es) |
BR (1) | BR112021019411A2 (es) |
CA (1) | CA3135407A1 (es) |
CO (1) | CO2021012719A2 (es) |
MX (1) | MX2021011816A (es) |
TW (1) | TW202104252A (es) |
WO (1) | WO2020205359A1 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL276365B2 (en) | 2018-02-01 | 2023-10-01 | Nkmax Co Ltd | A method for the production of natural killer cells and a preparation for cancer treatment |
JP2021522798A (ja) * | 2018-05-03 | 2021-09-02 | ボード オブ リージェンツ, ザ ユニバーシティ オブ テキサス システムBoard Of Regents, The University Of Texas System | 免疫チェックポイント遮断によりキメラ抗原受容体を発現するように操作されたナチュラルキラー細胞 |
WO2023164455A2 (en) * | 2022-02-23 | 2023-08-31 | Aloe Therapeutics Inc | Compositions and methods to modulate the immune system |
CN115896016B (zh) * | 2022-09-07 | 2023-09-12 | 普华赛尔生物医疗科技有限公司 | 培养组合物及其在培养免疫细胞中的应用 |
WO2024058589A1 (ko) * | 2022-09-16 | 2024-03-21 | 한국과학기술연구원 | 유전자 가위 넉-인을 이용하여 제조한 키메릭 항원 수용체 세포 및 이의 용도 |
US20240228959A9 (en) * | 2022-10-10 | 2024-07-11 | Kite Pharma, Inc. | Large scale car-t immune cell manufacturing method utilizing lentiviral vector transfection |
CN116168765B (zh) * | 2023-04-25 | 2023-08-18 | 山东大学 | 基于改进strobemer的基因序列生成方法及系统 |
CN116769722B (zh) * | 2023-07-04 | 2024-07-16 | 杭州荣谷生物科技有限公司 | 功能增强型car-nk细胞、其制备方法及其在免疫疗法中的应用 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107868791B (zh) * | 2016-09-26 | 2021-11-23 | 阿思科力(苏州)生物科技有限公司 | 一种加强型Slit2 CAR-T和CAR-NK细胞制备方法和应用 |
KR20240059648A (ko) * | 2017-04-19 | 2024-05-07 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | 조작된 항원 수용체를 발현하는 면역 세포 |
JP2021522798A (ja) * | 2018-05-03 | 2021-09-02 | ボード オブ リージェンツ, ザ ユニバーシティ オブ テキサス システムBoard Of Regents, The University Of Texas System | 免疫チェックポイント遮断によりキメラ抗原受容体を発現するように操作されたナチュラルキラー細胞 |
CN112424342A (zh) * | 2018-05-08 | 2021-02-26 | 生命科技公司 | 用于培养和扩增细胞的组合物和方法 |
-
2020
- 2020-03-25 BR BR112021019411A patent/BR112021019411A2/pt unknown
- 2020-03-25 MX MX2021011816A patent/MX2021011816A/es unknown
- 2020-03-25 JP JP2021557909A patent/JP2022519935A/ja active Pending
- 2020-03-25 WO PCT/US2020/024671 patent/WO2020205359A1/en unknown
- 2020-03-25 CN CN202080032042.7A patent/CN113811604A/zh active Pending
- 2020-03-25 KR KR1020217035535A patent/KR20220004992A/ko unknown
- 2020-03-25 CA CA3135407A patent/CA3135407A1/en active Pending
- 2020-03-25 EP EP20782753.6A patent/EP3947647A4/en active Pending
- 2020-03-25 US US17/593,085 patent/US20220325245A1/en active Pending
- 2020-03-25 AU AU2020254420A patent/AU2020254420A1/en active Pending
- 2020-03-27 TW TW109110593A patent/TW202104252A/zh unknown
- 2020-03-27 AR ARP200100857A patent/AR118510A1/es unknown
-
2021
- 2021-09-27 CO CONC2021/0012719A patent/CO2021012719A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
BR112021019411A2 (pt) | 2021-11-30 |
EP3947647A4 (en) | 2023-01-04 |
WO2020205359A1 (en) | 2020-10-08 |
TW202104252A (zh) | 2021-02-01 |
CN113811604A (zh) | 2021-12-17 |
AU2020254420A1 (en) | 2021-11-11 |
KR20220004992A (ko) | 2022-01-12 |
EP3947647A1 (en) | 2022-02-09 |
MX2021011816A (es) | 2021-10-22 |
JP2022519935A (ja) | 2022-03-25 |
CO2021012719A2 (es) | 2021-10-20 |
US20220325245A1 (en) | 2022-10-13 |
CA3135407A1 (en) | 2020-10-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR118510A1 (es) | Métodos para la producción de células car-nk y sus usos | |
CO2019006485A2 (es) | Anticuerpos y metodos de su utilizacion | |
BR112017014551A2 (pt) | ?anticorpo, construção de ácido nucleico, vetor de expressão, célula hospedeira, composição, métodos para tratamento de uma doença, para produção de um anticorpo biespecífico e para detecção da possível ocorrência de reticulação entre células com expressão de cd3 e cd20 em uma amostra derivada de um paciente, uso de um anticorpo biespecífico, e, kit? | |
DOP2019000056A (es) | Anticuerpos anti-pd-1 y sus usos | |
CL2020001151A1 (es) | Receptores de antígenos quiméricos específicos para el antígeno de maduración de células b y polinucleótidos que codifican los mismos. | |
CL2018003153A1 (es) | Moléculas de anticuerpo para el tratamiento del cáncer. | |
CL2016002004A1 (es) | Anticuerpos anti-jagged1 y métodos de uso | |
CL2017001289A1 (es) | Compuestos bicíclicos fusionados, sus composiciones y su uso para el tratamiento de enfermedades relacionadas con la modulación del receptor x farnesoide (fxr). | |
AR105433A1 (es) | Métodos para mejorar la eficacia y expansión de las células inmunes | |
BR112018067679A2 (pt) | células que expressam múltiplas moléculas do receptor de antígeno quimérico (car) e seu uso | |
ECSP18094829A (es) | Anticuerpos anti-cd40 y sus usos | |
CO2017000507A2 (es) | Receptor quimérico de antígeno bcma | |
AR103726A1 (es) | Cristales de anticuerpos monoclonales anti-pd-1 humanos | |
CL2019001646A1 (es) | Anticuerpos anti-ox40 y sus usos. | |
MX2020004243A (es) | Receptores de anticuerpos y de antigenos quimericos especificos para el antigeno de maduracion de celulas b. | |
EA202090931A3 (ru) | Композиции и способы перепрограммирования tcr с помощью гибридных белков | |
CL2019000836A1 (es) | Construcciones de inmunoglobulina heterodiméricas y métodos de preparación de las mismas. | |
AR101845A1 (es) | Anticuerpos anti-her2 e inmunoconjugados | |
CO2020013392A2 (es) | Receptores quiméricos de dll3 y métodos para su uso | |
CL2021001628A1 (es) | Anticuerpo humanizado anti-pd-1 humana | |
MX2020004801A (es) | Polipeptidos de fusion biespecificos y sus metodos de uso. | |
CO7240399A2 (es) | Proteínas fijadoras de antígeno antagonistas del receptor de acción dual y sus usos | |
AR095348A1 (es) | Medios de cultivo celular y métodos de producción de anticuerpos | |
NI202000051A (es) | Anticuerpos monoclonales y métodos para utilizar los mismos. | |
NI201600127A (es) | PROTEÍNAS DE FUSIÓN TATk-CDKL5, COMPOSICIONES FORMULACIONES Y USO DE ESTA. |